Theyre wise guides on your road toward a brighter future
In 2025, the company reported a slight 0.21% YoY revenue decline, reflecting portfolio dynamics: Eliquis ($14.44B) continues to anchor the business with strong demand in anticoagulation, Opdivo ($10.04B) remains a cornerstone in immuno-oncology across multiple indications, and Orencia ($3.7B) provides steady growth in immunology, partially offset by pressures from legacy products
That said, competition is coming: Pfizers cotadutide (dual agonist) is in late-stage trials, and if approved, could eat into Lillys share
For patients with pre-existing diabetic retinopathy, ophthalmologic follow-up is recommended, particularly during periods of rapid glycemic improvement
Eat smaller meals: this may reduce nausea, bloating, and reflux
Bear in mind that researchers still dont know exactly how common these effects are, but studies suggest GLP-1s may affect taste perception